FACTORS PREDICTING RESPONSE TO CHEMOTHERAPY AND SURVIVAL IN PATIENTS WITH METASTATIC OR RECURRENT SQUAMOUS-CELL CERVICAL-CARCINOMA - A MULTIVARIATE-ANALYSIS

被引:22
作者
ZANETTA, G
TORRI, W
BOCCIOLONE, L
LUCCHINI, V
MANGIONI, C
机构
[1] S GERARDO HOSP,DEPT PATHOL,MONZA,ITALY
[2] UNIV MILAN,BRANCH 3,MILAN,ITALY
[3] IST RIC FARMACOL MARIO NEGRI,CANC CLIN EPIDEMIOL LAB,MILAN,ITALY
关键词
D O I
10.1006/gyno.1995.1183
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Different regimens of chemotherapy have been proposed with contradictory results in patients with metastatic and recurrent cervical carcinoma: this seems mainly due to the lack of information about prognostic factors. This study was aimed at identifying significant factors predicting response to treatment and survival in 140 patients treated with chemotherapy for advanced, recurrent, or persistent squamous cell cervical carcinoma. Age, performance status, histologic type and grade, previous irradiation, interval from start of primary treatment and from irradiation, site of tumor, and therapeutic regimen were considered as possible predictors of response and survival in multivariate analysis. By multivariate analysis, only performance status and interval from irradiation (>1 year) were significant in predicting response to treatment, whereas interval from first diagnosis, site of tumor, and response to treatment were significant in predicting survival. None of the polychemotherapy regimens significantly improved survival, despite a fourfold increase in the costs when compared to the least expensive monochemotherapy regimen. Ethical and economical concerns should be considered when proposing aggressive regimens to the patients. Factors such as site of tumor, performance status, and interval from first treatment should be considered as minimal requirements for correct evaluation of newly proposed regimens. (C) 1995 Academic Press, Inc.
引用
收藏
页码:58 / 63
页数:6
相关论文
共 30 条
[1]  
Chung C.K., Nahhas W.A., Stryker J.A., Mortel R., Treatment outcome of recurrent cervical cancer, J. Surg. Oncol., 24, pp. 5-10, (1983)
[2]  
Thigpen T., Shingleton H., Homesley H., Lagasse L., Blessing J., As-Dichlorodiamminoplatinum(II) in the treatment of gynecologic malignancies: Phase II trials by the Gynecologic Oncology Group, Cancer Treat. Rep., 63, pp. 1549-1555, (1979)
[3]  
Bonomi P., Blessing J.A., Stehman F.B., Disaia P.H., Walton L., Major F.J., Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: A Gynecologic Oncology Group study, J. Clin. Oncol., 3, pp. 1079-1085, (1985)
[4]  
Thigpen T., Shingleton H., Homesley H., Lagasse L., Blessing J., M-Platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group, Cancer, 48, pp. 899-903, (1981)
[5]  
Friedlander M., Kaye S.B., Sullivan A., Atkinson K., Elliott P., Coppleson M., Et al., Cervical carcinoma: A drug-responsive tumor-Experience with combined cisplatin, vinblastine and bleomycin therapy, Gynecol. Oncol., 16, pp. 275-281, (1983)
[6]  
Rustin G.J.S., Newlands E.S., Southcott B.M., Singer A., Cisplatin, vincristine, methotrexate and bleomycin (POMB) as initial or palliative chemotherapy for carcinoma of the cervix, Br. J. Obstet. Gynecol., 94, pp. 1205-1211, (1987)
[7]  
Blackledge G., Buxton E.J., Mould J.J., Monaghan J., Paterson M., Tobias J., Et al., Phase II studies of ifosfamide alone and in combination in cancer of the cervix, Cancer Chemother. Pharmacol. Suppl., pp. 12-16, (1990)
[8]  
Daghestani A.N., Hakes T.B., Lynch G., Lewis J.L., Cervix carcinoma: Treatment with combination cisplatin and bleomycin, Gynecol. Oncol., 16, pp. 334-339, (1983)
[9]  
Chambers S.K., Flynn S.D., Del Prete S.A., Chambers J.T., Schwartz P.E., Bleomycin, vincristine, mitomycin C, and c/s-platinum in gynecologic squamous cell carcinoma: A high incidence of pulmonary toxicity, Gynecol Oncol, 32, pp. 303-309, (1989)
[10]  
Ramm K., Vergote I.B., Kaem J., Trope C.G., Bleomycin-ifosfam-ide-c/i-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: A second look, Gynecol Oncol, 46, pp. 203-207, (1992)